The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.

What will Pharma of the Future Look Like?

In a recent MedicinMan Poll on LinkedIn, it was...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Lifetime Value of a Patient: Why Indian Pharma must Transition from Product-centric Selling to Patient-centric Healthcare

Introduction For decades, the Indian pharmaceutical industry has measured success...

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

The Wealth of Pharma Nations: Top 25 Pharma Blockbusters

The economic footprint of a truly historic pharmaceutical blockbuster...

Oxytocin Maternal Deaths in Kota: Death in a Vial

When a vial contains only water, the failure is...

Innovation Without Access to Millions of Poor People is Unethical

What the Trikafta Stand-Off Teaches Us About the Future...

Marketing

Lifetime Value of a Patient: Why Indian Pharma must Transition from Product-centric Selling to Patient-centric Healthcare

Introduction For decades, the Indian pharmaceutical industry has measured success...

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

The Wealth of Pharma Nations: Top 25 Pharma Blockbusters

The economic footprint of a truly historic pharmaceutical blockbuster...

Oxytocin Maternal Deaths in Kota: Death in a Vial

When a vial contains only water, the failure is...

Innovation Without Access to Millions of Poor People is Unethical

What the Trikafta Stand-Off Teaches Us About the Future...

Policies/Sales

Lifetime Value of a Patient: Why Indian Pharma must Transition from Product-centric Selling to Patient-centric Healthcare

Introduction For decades, the Indian pharmaceutical industry has measured success...

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

The Wealth of Pharma Nations: Top 25 Pharma Blockbusters

The economic footprint of a truly historic pharmaceutical blockbuster...

Oxytocin Maternal Deaths in Kota: Death in a Vial

When a vial contains only water, the failure is...

Innovation Without Access to Millions of Poor People is Unethical

What the Trikafta Stand-Off Teaches Us About the Future...

Strategy

Lifetime Value of a Patient: Why Indian Pharma must Transition from Product-centric Selling to Patient-centric Healthcare

Introduction For decades, the Indian pharmaceutical industry has measured success...

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

The Wealth of Pharma Nations: Top 25 Pharma Blockbusters

The economic footprint of a truly historic pharmaceutical blockbuster...

Oxytocin Maternal Deaths in Kota: Death in a Vial

When a vial contains only water, the failure is...

Innovation Without Access to Millions of Poor People is Unethical

What the Trikafta Stand-Off Teaches Us About the Future...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Legal Scrutiny

The October 2016 Issue of MedicinMan features articles by K. Hariram, Vivek Hattangadi, Anup Soans and has a special focus on ethics and morals in the healthcare profession. Other topics covered include new product launches, the role of emotions in pharma sales and sales coaching.

Indian Pharma’s November 2025: How GLP-1s Rewired the Market

Indian pharma wrapped up November 2025 with serious velocity....

Why Most AI Healthcare Tools Stall at the Pilot Stage

Artificial intelligence (AI) in healthcare consistently demonstrates remarkable technical...

Medical Reps will Remain – What will be their Future Role?

There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it? “Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s. The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest. “Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.